Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.54 |
| ▸ | HRH2 | P25021 | 15/20 | 0.54 |
| ▸ | HRH1 | P35367 | 15/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3127684 | 0.95 | KCNH2 (0.57) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL3119483 | 0.92 | KCNH2 (0.52) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL3119858 | 0.91 | KCNH2 (0.58) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2966798 | 0.91 | KCNH2 (0.53) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2960597 | 0.88 | MEN1 (0.56) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2956719 | 0.86 | KCNA5 (0.53) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL3124752 | 0.84 | KCNH2 (0.48) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2967582 | 0.84 | KCNH2 (0.52) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2963123 | 0.83 | KCNH2 (0.56) | KCNH2HRH3HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL3132895 | 0.83 | KCNH2 (0.47) | KCNH2HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648985-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HRH3 437/4885HRH2 616/4885 |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HRH3 437/4885HRH2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.